APA (7th ed.) Citation

Fang Wang, Xiaofei Li, Yanting Shi, He Zhou, Gang Yang, Ruixia Li, . . . Jie Liang. (2023). Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Fang Wang, Xiaofei Li, Yanting Shi, He Zhou, Gang Yang, Ruixia Li, Tong Wu, and Jie Liang. Efficacy and Safety of Adalimumab Biosimilar (HS016) in Inflammatory Bowel Disease from the Real-world Study. Frontiers Media S.A., 2023.

MLA (9th ed.) Citation

Fang Wang, et al. Efficacy and Safety of Adalimumab Biosimilar (HS016) in Inflammatory Bowel Disease from the Real-world Study. Frontiers Media S.A., 2023.